October 10, 2012
With roughly 18,000 doses of an injectable steroid being voluntarily recalled due to contamination, the Centers for Disease Control and Prevention (CDC) announced 12 cases of infection have been reported in Indiana. According to NECN News, the approximately 1,500 patients who were exposed to the deadly strain of Aspergillus Meningitis received the injections at six different healthcare facilities across the state located in Elkhart, Evansville, Fort Wayne, South Bend, Terre Haute, and Columbus.
The injectable steroid, methylprednisolone acetate, was manufactured by the New England Compounding Center in Framingham, Massachusetts, where it was contaminated with the common leaf fungus. Patients who contracted the fungal meningitis will experience headaches, nausea, dizziness, and fever. They may also experience stroke-like symptoms due to inflammation around the brain and spinal cord. Patients exposed to the disease have been instructed to seek medical care immediately if they display any symptoms of the drug injury.
So far, the outbreak has been responsible for a dozen deaths, and more than 119 people have been infected across 23 states. Experts expect the number of infected patients to continue to rise over the next several weeks.
The Indiana Disability Lawyers with Fleschner, Stark, Tanoos & Newlin believe drug manufacturers have a responsibility to supply consumers with products that are safe. That’s why the firm would urge anyone who has suffered negative effects from medication given by a healthcare professional to discuss your rights with a qualified attorney immediately.
Fleschner, Stark, Tanoos & Newlin
N/aThe financial burden that often comes with a serious injury can be too much for many people to bear. Unexpected medical debt, damaged personal property, and the sudden loss of income can impact the budgets of most families. The good news is that a successful injury claim could help reduce that financial strain after a serious accident. Get in touch with a Terre Haute personal injury lawyer with Fleschner, Stark, Tanoos & Newlin to learn more.
Copyright ©2024 Fleschner, Stark, Tanoos & Newlin,